An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 41% Undervalued

An Intrinsic Calculation For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Suggests It's 41% Undervalued
The analyst price target for VRTX is 38% lower than the estimated fair value. An analysis using the Discounted Cash Flow model will help determine if the current share price of Vertex Pharmaceuticals (NASDAQ:VRTX) accurately reflects its intrinsic value.